G&A at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The official record: Cytokinetics’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's G&A?
- Cytokinetics (CYTK) reported G&A of $91.72M in Q4 2025.
- How has Cytokinetics's G&A changed year-over-year?
- Cytokinetics's G&A increased by 47.1% year-over-year, from $62.34M to $91.72M.
- What is the long-term trend for Cytokinetics's G&A?
- Over 4 years (2021 to 2025), Cytokinetics's G&A has grown at a 30.9% compound annual growth rate (CAGR), from $96.8M to $284.27M.
- What does G&A mean?
- The overhead costs of running the corporate side of the business.
- How do you interpret G&A?
- An increase relative to revenue may indicate operational inefficiency or scaling of corporate infrastructure, while a decrease suggests cost discipline.
- How does G&A compare across companies?
- Varies by company size and stage; high relative G&A is common in early-stage companies building out their corporate functions.